6.88
price down icon12.58%   -0.99
after-market Handel nachbörslich: 6.79 -0.09 -1.31%
loading

Cartesian Therapeutics Inc Aktie (RNAC) Neueste Nachrichten

pulisher
01:55 AM

Cartesian Therapeutics (RNAC) to Release Earnings on Thursday - MarketBeat

01:55 AM
pulisher
Mar 02, 2026

Published on: 2026-03-02 22:13:30 - baoquankhu1.vn

Mar 02, 2026
pulisher
Mar 02, 2026

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Mar 02, 2026
pulisher
Mar 01, 2026

Cartesian Therapeutics to present at TD Cowen Health Care Conference in Boston - Traders Union

Mar 01, 2026
pulisher
Feb 27, 2026

RNAC Should I Buy - Intellectia AI

Feb 27, 2026
pulisher
Feb 26, 2026

Cartesian Therapeutics, Inc. (RNAC): Biotechnology Innovator With A 350% Potential Upside - DirectorsTalk Interviews

Feb 26, 2026
pulisher
Feb 26, 2026

Cartesian Therapeutics, Inc. (RNAC) upgraded to buy: What does it mean for the stock? - MSN

Feb 26, 2026
pulisher
Feb 24, 2026

Published on: 2026-02-25 09:47:28 - baoquankhu1.vn

Feb 24, 2026
pulisher
Feb 24, 2026

Aug Sentiment: What is the earnings history of Cartesian Therapeutics IncWeekly Market Outlook & Daily Chart Pattern Signal Reports - baoquankhu1.vn

Feb 24, 2026
pulisher
Feb 23, 2026

Cartesian Therapeutics to Participate in Upcoming Investor Conferences - Bitget

Feb 23, 2026
pulisher
Feb 21, 2026

What drives Cartesian Therapeutics Inc.’s stock priceQuarterly Trade Review & Real-Time Buy Zone Alerts - mfd.ru

Feb 21, 2026
pulisher
Feb 20, 2026

Institution Moves: What’s the MACD signal for Cartesian Therapeutics Inc.2025 Buyback Activity & Smart Investment Allocation Insights - mfd.ru

Feb 20, 2026
pulisher
Feb 20, 2026

Cartesian Therapeutics, Inc. (RNAC) Investor Outlook: Unpacking a 435.71% Potential Upside in Biotech - DirectorsTalk Interviews

Feb 20, 2026
pulisher
Feb 17, 2026

Analyst Upgrade: Is Cartesian Therapeutics Inc attractive for institutional investorsEarnings Recap Report & Low Volatility Stock Recommendations - baoquankhu1.vn

Feb 17, 2026
pulisher
Feb 16, 2026

Trading Recap: What are Zenas BioPharma Incs growth leversMarket Trend Review & Verified Entry Point Detection - baoquankhu1.vn

Feb 16, 2026
pulisher
Feb 13, 2026

Is Cartesian Therapeutics Inc. stock positioned well for digital economyTrade Volume Summary & Community Verified Trade Signals - mfd.ru

Feb 13, 2026
pulisher
Feb 12, 2026

Is Cartesian Therapeutics Inc.’s ROE strong enoughWeekly Gains Report & Risk Managed Investment Entry Signals - mfd.ru

Feb 12, 2026
pulisher
Feb 11, 2026

FMR LLC Reduces Stake in Cartesian Therapeutics Inc: A Strategic Portfolio Adjustment - GuruFocus

Feb 11, 2026
pulisher
Feb 11, 2026

Is Cartesian Therapeutics Inc. a defensive stockJuly 2025 Setups & Free Low Drawdown Momentum Trade Ideas - mfd.ru

Feb 11, 2026
pulisher
Feb 06, 2026

Can JCTC stock outperform in a bear market2025 Geopolitical Influence & Advanced Technical Signal Analysis - baoquankhu1.vn

Feb 06, 2026
pulisher
Feb 05, 2026

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Feb 05, 2026
pulisher
Feb 05, 2026

Cartesian Therapeutics, Inc. (RNAC) Stock Analysis: Exploring a 420% Potential Upside in Biotechnology - DirectorsTalk Interviews

Feb 05, 2026
pulisher
Feb 03, 2026

Cartesian Therapeutics (RNAC) Issues New Stock Options to Employ - GuruFocus

Feb 03, 2026
pulisher
Feb 03, 2026

Cartesian Therapeutics Announces New Employment Inducement Grants - marketscreener.com

Feb 03, 2026
pulisher
Feb 03, 2026

Cartesian Therapeutics (NASDAQ:RNAC) Shares Down 0.6%Here's What Happened - MarketBeat

Feb 03, 2026
pulisher
Jan 31, 2026

Will Cartesian Therapeutics (NASDAQ:RNAC) Spend Its Cash Wisely? - Sahm

Jan 31, 2026
pulisher
Jan 29, 2026

Cartesian Therapeutics, Inc. (RNAC) Stock Analysis: Can a 388.62% Upside Fuel Your Investment Strategy? - DirectorsTalk Interviews

Jan 29, 2026
pulisher
Jan 27, 2026

Smart Money: Is Cartesian Therapeutics Inc trading at a discountJuly 2025 Trends & Weekly High Return Stock Forecasts - baoquankhu1.vn

Jan 27, 2026
pulisher
Jan 26, 2026

Stop Loss: Will Cartesian Therapeutics Inc outperform during market ralliesJuly 2025 Momentum & Real-Time Volume Spike Alerts - baoquankhu1.vn

Jan 26, 2026
pulisher
Jan 25, 2026

Aug Mood: Is Cartesian Therapeutics Inc stock a top performer YTDJuly 2025 Volume & Daily Risk Controlled Trade Plans - baoquankhu1.vn

Jan 25, 2026
pulisher
Jan 25, 2026

Pharma News: Does Cartesian Therapeutics Inc have declining or rising EPSQuarterly Trade Summary & Low Risk Investment Opportunities - baoquankhu1.vn

Jan 25, 2026
pulisher
Jan 22, 2026

Published on: 2026-01-22 19:08:46 - mfd.ru

Jan 22, 2026
pulisher
Jan 14, 2026

Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.

Jan 14, 2026
pulisher
Jan 14, 2026

Cartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Jan 14, 2026
pulisher
Jan 13, 2026

Risk Check: Is Cartesian Therapeutics Inc benefiting from interest rate changes2025 Biggest Moves & Risk Managed Investment Entry Signals - baoquankhu1.vn

Jan 13, 2026
pulisher
Jan 11, 2026

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Jan 11, 2026
pulisher
Jan 11, 2026

Cartesian Therapeutics (NASDAQ:RNAC) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - Defense World

Jan 11, 2026
pulisher
Jan 10, 2026

Why Cartesian Therapeutics Inc. stock is a value investor pickMarket Growth Summary & Reliable Price Action Trade Plans - ulpravda.ru

Jan 10, 2026
pulisher
Jan 09, 2026

Cartesian Therapeutics (RNAC): Needham Raises Price Target to $4 - GuruFocus

Jan 09, 2026
pulisher
Jan 09, 2026

Myasthenia Gravis Market Positioned for Accelerated - openPR.com

Jan 09, 2026
pulisher
Jan 09, 2026

Cartesian Therapeutics highlights recent progress and outlines 2026 outlook - marketscreener.com

Jan 09, 2026
pulisher
Jan 09, 2026

Cartesian Therapeutics Reports Progress in Phase 3 AURORA Trial of Descartes-08 for Myasthenia Gravis and Initiates Pediatric Trial for Juvenile Dermatomyositis - Quiver Quantitative

Jan 09, 2026
pulisher
Jan 09, 2026

Cartesian Therapeutics Highlights 2026 Strategic Priorities - TradingView — Track All Markets

Jan 09, 2026
pulisher
Jan 09, 2026

Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook - GlobeNewswire

Jan 09, 2026
pulisher
Jan 08, 2026

What momentum indicators show for Cartesian Therapeutics Inc. stockQuarterly Portfolio Review & AI Optimized Trading Strategy Guides - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Is Cartesian Therapeutics Inc. stock resilient to inflationJuly 2025 Final Week & Growth Focused Stock Pick Reports - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Cartesian Therapeutics (NASDAQ:RNAC) CFO Sells $72,230.62 in Stock - MarketBeat

Jan 08, 2026
pulisher
Jan 08, 2026

Is Cartesian Therapeutics Inc. stock supported by innovation pipelineWeekly Stock Report & Free Technical Pattern Based Buy Signals - ulpravda.ru

Jan 08, 2026
pulisher
Jan 08, 2026

Cartesian Therapeutics, Inc. (RNAC) Stock Analysis: Exploring a 354.71% Potential Upside in the Biotech Frontier - DirectorsTalk Interviews

Jan 08, 2026
pulisher
Jan 06, 2026

Is Cartesian Therapeutics Inc. stock a buy before product launches2026 world cup usa national team quarterfinals defensive leaders transition play group prediction preview - Улправда

Jan 06, 2026
pulisher
Jan 06, 2026

Cartesian Therapeutics, Inc.Common Stock (NQ: RNAC - FinancialContent

Jan 06, 2026
pulisher
Dec 27, 2025

What analysts say about Cartesian Therapeutics Inc 1S70 stockPortfolio Allocation Tips & Small Investment Wealth Growth - earlytimes.in

Dec 27, 2025
$45.68
price down icon 3.69%
$53.83
price down icon 6.87%
$29.72
price up icon 0.68%
$101.95
price down icon 1.78%
$143.57
price down icon 4.21%
biotechnology ONC
$292.94
price down icon 2.03%
Kapitalisierung:     |  Volumen (24h):